NDA 215179 · Shilpa
Pemetrexed
Pemetrexed Disodium · Intravenous
Last checked: Nov 20, 2026Latest source record: Nov 15, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
May 22, 2023
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1,474
328 Phase 3, 251 recruiting
FAERS reports
26,175
25,665 serious, 4,553 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 8, 2025.
1. INDICATIONS AND USAGE PEMRYDI RTU ® is a folate analog metabolic inhibitor indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. ( 1.1 ) in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC. ( 1.1 ) as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. ( 1.1 ) as a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy. ( 1.1 ) Limitations of Use: PEMRYDI RTU is not indicated for the treatment of patients with squamous cell, non-small cell lung cancer. ( 1.1 ) initial treatment, in combination with cisplatin, of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery. ( 1.2 ) 1.1 Non-Squamous Non-Small Cell Lung Cancer (NSCLC) PEMRYDI RTU ® is indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC. as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. as a single agent for the treatment of patients with...
Mechanism: Pemetrexed is a folate analog metabolic inhibitor that disrupts folate-dependent metabolic processes essential for cell replication. In vitro studies show that pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase (GARFT), which are folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides. Pemetrexed is taken into cells by membrane carriers such as the reduced folate carrier and membrane folate binding protein transport systems. Once in the cell, pemetrexed is converted to polyglutamate...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
3 products under this application
- PEMETREXED · PEMETREXED DISODIUM EQ 1GM/100ML BASE (10MG/ML) · SOLUTION, INTRAVENOUS · Prescription
- PEMETREXED · PEMETREXED DISODIUM EQ 100MG/10ML BASE (10MG/ML) · SOLUTION, INTRAVENOUS · Prescription
- PEMETREXED · PEMETREXED DISODIUM EQ 500MG/50ML BASE (10MG/ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Pemetrexed Disodium" as an intervention, any sponsor and status, largest first.
- Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint InhibitorsPivotal-lookingRecruiting
Hunan Province Tumor HospitalAcademic, hospital or other
NCT05055908 · 12,000 participants (planned) · Start Oct 1, 2021 · Primary completion Jul 1, 2025
Drug: Pemetrexed plus Pembrolizumab; Pembrolizumab and 1 more · For: Lung Cancer
Sites: Changsha, China
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT02194738 · 7,458 participants · Start Sep 26, 2014 · Primary completion Dec 3, 2025
Drug: Carboplatin; Cisplatin and 8 more · For: Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage II Lung Non-Small Cell Cancer AJCC v7; Stage IIA Lung Cancer AJCC v8 and 4 more
Sites: Birmingham, Alabama; Daphne, Alabama; Mobile, Alabama · 1,660 sites in all
- Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationRecruiting
Hunan Province Tumor HospitalAcademic, hospital or other
NCT04322890 · 6,000 participants (planned) · Start Apr 16, 2020 · Primary completion Dec 24, 2026
Drug: Osimertinib; Alectinib 150 MG and 3 more · For: Non Small Cell Lung Cancer; EGFR Gene Mutation; ALK Gene Mutation and 2 more
Sites: Changsha, China
- Optimal Standard Treatment Selection for Solid Tumor Patients by Biologically-informed Multi-agent SystemNot yet recruiting
NING LIAcademic, hospital or other
NCT06824792 · 3,000 participants (planned) · Start Mar 1, 2025 · Primary completion Feb 29, 2028
Drug: Biologically-informed multi-agent system (Quasar) including targeted drugs Osimertinib, chemotherapy pemetrexed, immunotherapy pembrolizumab et al. approved by China CDE. · For: Advanced Solid Tumors
Sites: Langfang, China
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT02477826 · 2,747 participants · Start Aug 5, 2015 · Primary completion Oct 25, 2024
Drug: Nivolumab; Ipilimumab and 5 more · For: Non-Small Cell Lung Cancer
Sites: Mobile, Alabama; San Francisco, California; New Haven, Connecticut · 290 sites in all
- A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung CancerPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT00087711 · 1,713 participants · Start Jul 2004 · Primary completion Jan 2007
Drug: pemetrexed; gemcitabine and 1 more · For: Non Small Cell Lung Carcinoma
Sites: Sacramento, California; Torrance, California; Jacksonville, Florida · 134 sites in all
- Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)Pivotal-lookingRecruiting
BioNTech SEIndustry
NCT06712316 · 1,580 participants (planned) · Start Jan 7, 2025 · Primary completion Jan 2029
Drug: Pumitamig; Pembrolizumab and 3 more · For: Non-small Cell Lung Cancer
Sites: Birmingham, Alabama; Anchorage, Alaska; Concord, California · 366 sites in all
- Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung CancerPivotal-lookingCompleted
ECOG-ACRIN Cancer Research GroupResearch network
NCT01107626 · 1,516 participants · Start Oct 25, 2010 · Primary completion Jan 31, 2019
Drug: Paclitaxel; Carboplatin and 2 more · For: Lung Cancer
Sites: Anniston, Alabama; Fairbanks, Alaska; Fairfield, California · 434 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- malignant neoplasm progression2,103
- anaemia1,501
- nausea1,248
- off label use1,239
- diarrhoea1,220
- neutropenia1,207
- disease progression1,191
- pancytopenia1,130
- thrombocytopenia1,086
- drug ineffective1,027
- vomiting947
- death943
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 61 |
| 2005 | 50 |
| 2006 | 28 |
| 2007 | 99 |
| 2008 | 136 |
| 2009 | 310 |
| 2010 | 532 |
| 2011 | 572 |
| 2012 | 438 |
| 2013 | 273 |
| 2014 | 321 |
| 2015 | 315 |
| 2016 | 530 |
| 2017 | 629 |
| 2018 | 1,047 |
| 2019 | 1,407 |
| 2020 | 1,528 |
| 2021 | 2,005 |
| 2022 | 2,510 |
| 2023 | 2,947 |
| 2024 | 3,811 |
| 2025 | 3,625 |
| 2026 | 3,001 |
Recalls
2 FDA enforcement reports for this application.
Jul 29, 2026 · Class II · Ongoing
Discolored solution. The firm has received market complaints reporting green to dark green discoloration in certain vials
Jul 29, 2026 · Class II · Ongoing
Discolored solution. The firm has received market complaints reporting green to dark green discoloration in certain vials
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Pemetrexed (Pemetrexed)
2024 spending
$29K
Beneficiaries
11
43 claims
Per beneficiary
$2,604
$201.14 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $28,649 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. · N Engl J Med 2018 · Clinical Trial, Phase III, Multicenter Study
- Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.
Planchard D, Jänne PA, Cheng Y, et al. · N Engl J Med 2023 · Clinical Trial, Phase III, Randomized Controlled Trial
- Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial.
Fang W, Zhao Y, Luo Y, et al. · JAMA 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC.
Jänne PA, Planchard D, Kobayashi K, et al. · N Engl J Med 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study.
Garassino MC, Gadgeel S, Speranza G, et al. · J Clin Oncol 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
Mok TS, Wu Y-L, Ahn M-J, et al. · N Engl J Med 2017 · Clinical Trial, Phase III, Comparative Study
Sponsor: Shilpa
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.